Comparative glycomic profiling in esophageal adenocarcinoma

Area of Science:

• Biochemistry
• Oncology
• Analytical Chemistry

Background:

• Aberrant glycosylation is a hallmark of cancer, involving altered cell surface proteins shed into circulation.
• Glycomic profiling of bodily fluids can reveal these cancer-associated glycan changes.
• Esophageal adenocarcinoma (EAC) progression involves distinct glycosylation patterns.

Purpose of the Study:

• To investigate differences in serum N-glycan profiles among healthy individuals, patients with Barrett's metaplasia, high-grade dysplasia, and EAC.
• To identify specific glycans that can serve as biomarkers for EAC detection and staging.

Main Methods:

• Serum N-glycans were enzymatically released from samples of healthy volunteers (N=18), Barrett's metaplasia (N=5), high-grade dysplasia (N=11), and EAC (N=50).
• Glycans were purified, permethylated, and analyzed using matrix-assisted laser desorption ionization-time of flight/time of flight (MALDI-TOF/TOF) mass spectrometry.
• Mass spectrometry data were processed to identify and quantify N-glycan structures.

Main Results:

• Significant differences in the intensities of 98 glycans were observed among the groups.
• Of these, 26 corresponded to known glycan structures.
• Eight specific glycans showed significant differences across all pairwise comparisons (normal vs. high-grade dysplasia, normal vs. EAC, high-grade dysplasia vs. EAC).

Conclusions:

• Comparative glycomic profiling of serum effectively identifies distinct glycan signatures associated with esophageal adenocarcinoma.
• A subset of identified glycans demonstrates potential as biomarkers for differentiating normal tissue, high-grade dysplasia, and EAC.
• Further validation is required to establish the clinical utility of these glycan biomarkers for esophageal cancer diagnosis.